Evidence map›Paper›PMID 41882098›Full record

ArticleLeukemia2026

Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity.

Yutong Tu, Xiaojia Cai, Zhaofan Tao, Ruisen Zhang, Xian Li, Beijing Chen, Hualin Zhang, Xiaobei Hu, Jiayi Ke, Xiaoya Chen and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yutong Tu *Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China.
Xiaojia Cai *Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Zhaofan TaoDepartment of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Ruisen ZhangSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Xian LiZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China.
Beijing ChenZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China.
Hualin ZhangDepartment of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID 0009-0004-7540-2626
Xiaobei HuZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China.ORCID 0000-0002-7765-1771
Jiayi KeDepartment of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xiaoya ChenDepartment of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xinyan BaiZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China.
Jia LiZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China. jli@simm.ac.cn.ORCID 0000-0003-3224-001X
Tianfeng XuDepartment of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. tfxu@simm.ac.cn.ORCID 0000-0001-8996-4065
Yubo ZhouZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China. ybzhou@simm.ac.cn.ORCID 0000-0002-0694-3697

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82273951
6 · The paper itself

Abstract

Cyclin-dependent kinase 7 (CDK7), a key regulator of cell cycle progression and transcriptional control, has emerged as a promising therapeutic target in acute leukemia. While CDK7 inhibitors have shown antileukemic activity, their clinical utility is often restricted by dose-dependent thrombocytopenia. To overcome this challenge, we developed and characterized a series of CDK7-selective PROTAC degraders. By engaging the VHL E3 ligase, which is minimally expressed in platelets, CXJ2080 achieves tumor-selective CDK7 degradation with remarkable potency and selectivity (a DC

Indexed as

Blood PlateletsCyclin-Dependent KinasesLeukemiaLeukemia, Myeloid, AcuteProtein Kinase InhibitorsAnimalsCell Line, TumorCyclin-Dependent Kinase-Activating KinaseHumansMiceProteolysis Targeting ChimeraXenograft Model Antitumor AssaysCDK7 protein, humanCyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesProtein Kinase InhibitorsProteolysis Targeting Chimera

Identifiers

PMID41882098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.